These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24643628)

  • 1. On target: genetically modified cells show promise in targeted immunotherapy for advanced blood cancers.
    Printz C
    Cancer; 2014 Apr; 120(7):929-30. PubMed ID: 24643628
    [No Abstract]   [Full Text] [Related]  

  • 2. One size does not fit all: personalized immune therapies poised to take center stage.
    Azvolinsky A
    J Natl Cancer Inst; 2013 May; 105(9):583-4. PubMed ID: 23591459
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adoptive immunotherapy using gene-modified T cells to express target-specific receptors against hematological malignancy].
    Fujiwara H
    Rinsho Ketsueki; 2014 Oct; 55(10):2162-74. PubMed ID: 25297783
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccine therapy and adoptive immunotherapy in hematologic malignancies.
    Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):373-4. PubMed ID: 18790443
    [No Abstract]   [Full Text] [Related]  

  • 5. Stay the course.
    Nat Med; 2014 Jun; 20(6):561. PubMed ID: 24901549
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction to a review series on emerging immunotherapies for hematologic diseases.
    Paczesny S; Pavletic SZ; Bollard CM
    Blood; 2018 Jun; 131(24):2617-2620. PubMed ID: 29728405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T-Cell Therapy Shows Promise in Multiple Hematologic Malignancies.
    Kahl KL
    Oncology (Williston Park); 2020 Jan; 34(1):20. PubMed ID: 32645201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T lymphocytes as therapeutic arsenal for patients with hematological malignancies.
    Montoro J; Piñana JL; Sanz J; Guerreiro M
    Curr Opin Oncol; 2018 Nov; 30(6):425-434. PubMed ID: 30124521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in T-cell immunotherapy for haematological malignancies.
    Rouce RH; Sharma S; Huynh M; Heslop HE
    Br J Haematol; 2017 Mar; 176(5):688-704. PubMed ID: 27897332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic potential of NK and NKT cell lines in hematopoietic malignancies.
    Hu Z
    Leuk Res; 2003 Oct; 27(10):879-81. PubMed ID: 12860005
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy for Hematologic Malignancies.
    Craddock C; Friedberg JW
    J Clin Oncol; 2021 Feb; 39(5):343-345. PubMed ID: 33434044
    [No Abstract]   [Full Text] [Related]  

  • 12. [The role of immunotherapy in the treatment of patients with hematologic neoplasms].
    Rukavitsyn OA
    Vopr Onkol; 2002; 48(2):186-92. PubMed ID: 12227066
    [No Abstract]   [Full Text] [Related]  

  • 13. Guest editorial: recent progress in gene therapy.
    Ozawa K
    Int J Hematol; 2014 Apr; 99(4):359-60. PubMed ID: 24609718
    [No Abstract]   [Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy for haematological malignancies.
    Selim AG; Tam CS
    Med J Aust; 2020 Nov; 213(9):404-406.e1. PubMed ID: 32951222
    [No Abstract]   [Full Text] [Related]  

  • 15. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 2():S133-S134. PubMed ID: 30686351
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of hematological malignancy-associated antigens and clinical applications.
    Fujiwara H
    Rinsho Ketsueki; 2009 May; 50(5):340-51. PubMed ID: 19483393
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 18. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.
    Schmid C; Kuball J; Bug G
    J Clin Oncol; 2021 Feb; 39(5):397-418. PubMed ID: 33434060
    [No Abstract]   [Full Text] [Related]  

  • 19. Game Changers in Treatment of Hematologic Malignancies.
    Goy A
    Oncology (Williston Park); 2019 Sep; 33(9):. PubMed ID: 31571178
    [No Abstract]   [Full Text] [Related]  

  • 20. Cellular immunotherapy in haematological malignancies.
    Reid CD
    Br J Haematol; 1999 Apr; 105 Suppl 1():7-10. PubMed ID: 10330926
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.